Literature DB >> 20550438

Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement.

Dalila Y Martínez1, Carlos Seas, Francisco Bravo, Pedro Legua, Cesar Ramos, Alfonso M Cabello, Eduardo Gotuzzo.   

Abstract

Granulomatous amoebic encephalitis caused by Balamuthia mandrillaris is an uncommon infection for which there is no optimal therapy. We describe a young, female patient who presented with extensive cutaneous and neurological involvement and who recovered after receiving prolonged treatment with miltefosine, fluconazole, and albendazole.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20550438     DOI： 10.1086/653609

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  28 in total

1.  Balamuthia mandrillaris amoebic encephalitis: an emerging parasitic infection.

Authors:  Francisco G Bravo; Carlos Seas
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis.

Authors:  W Matthew Linam; Mubbasheer Ahmed; Jennifer R Cope; Craig Chu; Govinda S Visvesvara; Alexandre J da Silva; Yvonne Qvarnstrom; Jerril Green
Journal:  Pediatrics       Date:  2015-02-09       Impact factor: 7.124

3.  Disseminated Balamuthia mandrillaris Infection.

Authors:  Katherine R Schafer; Neil Shah; M I Almira-Suarez; Jennifer M Reese; George M Hoke; James W Mandell; Sharon L Roy; Govinda Visvesvara
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

4.  The Epidemiology and Clinical Features of Balamuthia mandrillaris Disease in the United States, 1974-2016.

Authors:  Jennifer R Cope; Janet Landa; Hannah Nethercut; Sarah A Collier; Carol Glaser; Melanie Moser; Raghuveer Puttagunta; Jonathan S Yoder; Ibne K Ali; Sharon L Roy
Journal:  Clin Infect Dis       Date:  2019-05-17       Impact factor: 9.079

5.  Transmission of Balamuthia mandrillaris through solid organ transplantation: utility of organ recipient serology to guide clinical management.

Authors:  A A Gupte; S N Hocevar; A S Lea; R D Kulkarni; D C Schain; M J Casey; I R Zendejas-Ruiz; W K Chung; C Mbaeyi; S L Roy; G S Visvesvara; A J da Silva; J Tallaj; D Eckhoff; J W Baddley
Journal:  Am J Transplant       Date:  2014-05-19       Impact factor: 8.086

Review 6.  Antiparasitic therapy.

Authors:  Shanthi Kappagoda; Upinder Singh; Brian G Blackburn
Journal:  Mayo Clin Proc       Date:  2011-06       Impact factor: 7.616

7.  Balamuthia mandrillaris and Acanthamoeba amebic encephalitis with neurotoxoplasmosis coinfection in a patient with advanced HIV infection.

Authors:  Paula Pietrucha-Dilanchian; Joseph C Chan; Amilcar Castellano-Sanchez; Alicia Hirzel; Panthipa Laowansiri; Claudio Tuda; Govinda S Visvesvara; Yvonne Qvarnstrom; Kenneth R Ratzan
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

8.  Assessment of blood-brain barrier penetration of miltefosine used to treat a fatal case of granulomatous amebic encephalitis possibly caused by an unusual Balamuthia mandrillaris strain.

Authors:  Sharon L Roy; Jane T Atkins; Rosemaria Gennuso; Danny Kofos; Rama R Sriram; Thomas P C Dorlo; Teresa Hayes; Yvonne Qvarnstrom; Zuzana Kucerova; B Joseph Guglielmo; Govinda S Visvesvara
Journal:  Parasitol Res       Date:  2015-09-02       Impact factor: 2.289

9.  Centrofacial Balamuthiasis: case report of a rare cutaneous amebic infection.

Authors:  Oliver H Chang; Fan Liu; Eleanor Knopp; Atis Muehlenbachs; Jennifer R Cope; Ibne Ali; Robert Thompson; Evan George
Journal:  J Cutan Pathol       Date:  2016-07-12       Impact factor: 1.587

10.  Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case.

Authors:  Jennifer R Cope; Dennis A Conrad; Naiomi Cohen; Manuel Cotilla; Alexandre DaSilva; Jonathan Jackson; Govinda S Visvesvara
Journal:  Clin Infect Dis       Date:  2015-12-17       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.